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Mesenchymal stem/stromal cells (MSCs) and fibroblasts are present in normal 
tissues to support tissue homeostasis. Both share common pathways and have a 
number of common features, such as a spindle-shaped morphology, connective 
tissue localization, and multipotency. In inflammation, a nonspecific response to 
injury, fibroblasts and MSC are the main players. Two mechanisms of their mode of 
action have been defined: immunomodulation and regeneration. Following tissue 
injury, MSCs are activated, and they multiply and differentiate, to mitigate the 
damage. With aging and, in particular, in degenerative disorders of the musculo-
skeletal system (i.e., joint and bone disorders), the regenerative capacity of MSCs 
appears to be lost or diverted into the production of other nonfunctional cell types, 
such as adipocytes and fibroblasts. Fibroblasts are stromal cells that provide the 
majority of the structural framework of almost all types of tissues; i.e., the stroma. 
As such, fibroblasts also have significant roles in tissue development, maintenance, 
and repair. In their immunosuppressive role, MSCs and fibroblasts contribute to the 
normal resolution of inflammation that is a prerequisite for successful tissue repair. 
In this chapter, we review the common and opposing properties of different tissue-
derived MSCs and fibroblasts under physiological and pathophysiological condi-
tions. We consider injury and age-related degeneration of various tissues, and also 
some immunological disorders. Specifically, we address the distinct and common 
features of both cell types in health and disease, with a focus on human synovial 
joints. Finally, we also discuss the possible approaches to boost the complementary 
roles of MSCs and fibroblasts, to promote successful tissue regeneration.
Keywords: Mesenchymal stem/stromal cells, fibroblasts, tissue injury,  
age-related tissue degeneration, tissue regeneration
1. Introduction
Mesenchymal stem/stromal cells (MSCs) represent tissue-resident progenitor 
cells with multi-differentiation potential in vivo (stem cells) and in vitro (stromal 
cells) [1]. Although MSCs were first described several decades ago [2, 3], their 
nature, roles, definitions, and even name remain to be fully defined. The largest 
bone of contention lies in their designation as stem cells. Even Arnold Caplan, 
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who first coined the term ‘mesenchymal stem cells’ [4], has suggested recently that 
it is time to change the name, to avoid unprecedented expectations of regrowth 
of new tissues and organs [5]. About 15 years ago, the International Society for 
Cellular Therapy set up minimal criteria for the definition of MSCs in vitro, which 
include plastic adherence, trilineage differentiation, and a set of negative and posi-
tive markers [6]. These initial efforts were further up-graded as the knowledge of 
the in-vitro properties of MSCs accumulated, in particular for their role in immuno-
modulation [7].
Great advances have been made in the in-vivo identification of human skeletal 
stem cells (SSCs). Following their identification in mouse bone marrow, Chan et al.  
unraveled the hierarchy of positive markers (i.e., podoplanin, CD73, CD164) and 
negative markers (i.e., CD146) of the self-renewing, multipotent human SSCs. 
These cells can be isolated from human fetal and adult adipose stroma following 
treatment with bone morphogenetic protein 2, and they can undergo local expan-
sion in response to acute skeletal injury [8]. In addition, the same group recently 
identified a way to boost the endogenous SSCs to aid in the repair of worn out 
cartilage in osteoarthritis [9].
In contrast to the huge advances made in the field of bone-marrow-derived 
MSCs, the identity and role of MSCs resident in other tissues are still largely 
unknown. Initially, MSCs were believed to be common progenitors of all musculo-
skeletal tissues. On this basis, several hypotheses on the developmental origins of 
MSCs were put forward. The pericyte hypothesis, for example, suggested that MSCs 
are pericytes and are thus common to every vascularized tissue [10]. However, 
Guimarães-Camboa et al. rejected this theory, and revealed that pericytes do not 
behave as stem cells during aging and injury [11]. They traced transcription fac-
tor Tbx18 (as a selective marker of pericytes and vascular smooth muscle cells) to 
follow the fate of these cells in aging and in injury models in multiple adult organs. 
In this way they showed that pericytes maintained their identity through aging 
and in diverse pathological settings, and hence did not significantly contribute to 
other cell lineages [11]. Currently, what we do know is that MSCs are tissue-specific 
progenitors that can differentiate into their tissue of origin [12, 13] and exhibit tis-
sue of origin-specific profiles and response to inflammatory stimuli [14]. Although 
MSCs have already been used in clinical practice in the form of cell injections for 
treatment of several degenerative disorders, unfortunately much of their reported 
anti-aging and regenerative potential remains unsupported [15, 16]. Hence, their 
potential in regenerative medicine is still largely underexploited.
Fibroblasts are historically even ‘older’ than MSCs, as they were first described 
over a century ago [17]. However the criteria for their definition is even more poorly 
established than that for MSCs [18–20]. Fibroblasts constitute the majority of the 
cells of the structural framework, or stroma, of almost all types of tissues [20]. Their 
main role is the secretion of extracellular matrix molecules, such as collagen, pro-
teoglycans, and others. As the different types of collagen are the major component 
of tissues such as bone, cartilage, and skin, fibroblasts also have significant roles in 
tissue development, maintenance, and repair. Fibroblasts from different tissues were 
long considered as functionally homogenous cells, however significant differences in 
transcriptome, epigenome and function were demonstrated for synovial fibroblasts 
from different anatomical locations in joints [21]. Under certain conditions, fibro-
blasts can also transform into more aggressive phenotypes and contribute to disease 
pathophysiology, such as in cancers and rheumatoid arthritis [22].
Mesenchymal stem/stromal cells and fibroblasts share numerous common 
features, as has been reviewed elsewhere [20, 23]. As these cells participate in the 
common pathways of tissue development, maintenance and healing, either working 
together or in opposition, this chapter provides an overview of recent studies on 
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these shared and opposing properties of MSCs and fibroblasts with a focus on tissue 
injury and age-related tissue degeneration, in particular in joint health and disease.
For the purpose of this review, we performed a literature search in PubMed 
according to the search terms and filters shown in Figure 1. To focus on human 
studies carried out in the past 5 years, we excluded all studies dealing with tumor 
Figure 1. 
The approach used to search and select the papers included in this review.
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research, which covers a particularly large research area. We included only those 
studies dealing with tissue injuries and regeneration, and age-related degeneration. 
Finally, we also discuss the options for diverting tissue healing processes toward 
morphological and functional regeneration, rather than the creation of poorly 
functioning scar tissue to cover such defects.
2.  MSCs and fibroblasts in general: their common and distinct 
properties
A summary of the recent studies that have compared various tissue-derived 
MSCs and fibroblasts face to face is provided in Table 1. A schematic representation 
of the distinct and common features of MSCs and fibroblasts in health and disease, 
with a focus on human synovial joints is shown in Figure 2.
Reference Source of MSCs Source of 
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2.1 Common properties: tissue remodeling and immunomodulation
In contrast to the extremely rare status of MSCs in almost all adult connec-
tive tissue (i.e., from 1 to 25 cells per 1,000,000 cells in bone marrow are MSCs 
[32, 33]), fibroblasts are the most abundant cell type in connective tissue [22]. 
Fibroblasts are the maintainers of extracellular matrix turnover, and they regulate 
several physiological processes. In contrast, MSCs are quiescent most of the time, 
but have self-renewing capacity. However, in response to certain stimuli, such as tis-
sue injury, MSCs respond promptly, resulting in their activation and proliferation, 
and their differentiation into the terminal cell types that are required for regenera-
tion following an injury [8, 33]. Both cell types can provide the stroma, in particular 
as collagen for tissues during injury and wound healing. However, it appears that 
the repair processes that result in formation of a functional tissue, such as collagen 
type II in cartilage injury, is a feature of MSCs, and particularly for those of the 
synovium [34]. Fibroblasts or other tissue-derived MSCs (e.g., bone marrow) might 
Reference Source of MSCs Source of 
fibroblasts
Methods Findings
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Both conditioned media 
have high concentrations 
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ATTC, American Type Culture Collection; FACS, fluorescence activated cell sorting; LPS, lipopolysaccharide, 
PBMC, peripheral blood mononuclear cells, PHA, phytohemagglutinin; FSP, fibroblast-specific protein; PDGFRβ, 
platelet derived growth factor receptor β.
Table 1. 
Overview of recent studies with face-to-face comparisons of various tissue-derived MSCs and fibroblasts.
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be responsible for the filling of defects in cartilage injury with only fibrous tissue; 
i.e., the fibrocartilage, which is a nonfunctional tissue [9, 35]. Although some early 
studies showed efficacy for fresh human skin allografts in the treatment of diabetic 
ulcers, severe burns, and other such injuries, recent studies have instead suggested 
that fibroblasts are more likely contaminants in such cell therapies, and thus they 
should be depleted so as not to impede the rejuvenation effects of stem cells [36]. 
There is also evidence that fibroblasts can undergo aggressive transformation in 
response to the tumor microenvironment, and thus contribute to disease patho-
physiology, such as in cancers [22].
Immunomodulation is a fundamental characteristic of all stroma, which 
includes, in particular, immunosuppressive effects [37]. Jones et al. showed that 
stromal cells (e.g., chondrocytes, fibroblasts from synovial joints, lung, skin) can 
inhibit proliferation of peripheral blood mononuclear cells following polyclonal 
stimuli. In contrast to parenchymal cells, stromal cells showed antiproliferative 
functions, irrespective of their differentiation potential and/or content of progeni-
tor cells [37].
During inflammation, proteins and lipids secreted by various cells act in a 
concerted fashion. Tahir et al. analyzed the formation of the most relevant inflam-
mation mediators, including proteins and lipids, in human fibroblasts and MSCs 
upon inflammatory stimulation and subsequent treatment with dexamethasone 
[24]. They showed that fibroblasts and MSCs have similar secretion profiles for 
stimulation and modulation of inflammation [24].
In contrast, there are also studies that have provided evidence of greater anti-
inflammatory and wound-healing features of MSCs in comparison to other stromal 
cells [25]. In an array of in-vitro tests to compare human artery-wall-derived MSCs 
with dermal fibroblasts and myofibroblasts, Pasanisi et al. showed some profound 
differences in the immunomodulatory properties between these cell types [25]. 
Figure 2. 
Schematic representation of the distinct and common features of MSCs and fibroblasts in health and disease, 
with a focus on human synovial joints. ECM, extracellular matrix.
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Both the dermal fibroblasts and myofibroblasts expressed very low levels of immu-
nomodulatory and inflammation-related genes, and had lower immunosuppressive 
potential for proliferation of peripheral blood mononuclear cells in comparison 
to the femoral artery MSCs. They also suggested that the two highly sought after 
translational abilities, as anti-inflammatory and wound healing activities, are 
unique features of MSCs [25].
Although MSCs and fibroblasts share common sources for their isolation, such 
as adipose tissue, muscle, and skin, most recent studies have used bone marrow 
as the source of MSCs and skin as the source of fibroblasts. Following their plastic 
adherence after isolation and in-vitro culture expansion, fibroblasts are morpholog-
ically indistinguishable from MSCs, as they both have a spindle-shaped morphology 
[20]. They also both express the same positive mesenchymal markers, and both lack 
hematopoietic markers [19]. They also both show trilineage differentiation; i.e., 
adipogenesis, osteogenesis, and chondrogenesis [36]. Hence, the minimal criteria 
set by the International Society for Cellular Therapy to define MSCs [6] can also 
define fibroblasts [20]. Despite great effort, the lack of a specific marker to distin-
guish between MSCs and fibroblasts represents a major limit in the study of these 
cells [25].
2.2 Distinct properties: transcriptome profile and migration capacity
Haydont et al. recently performed a wide comparison of skin fibroblasts from 
three different locations in the deep dermis and hypodermis with five different 
tissue-derived MSCs [26]. Using genome-wide transcriptome profiling, they 
showed a clear ‘fibroblast’ molecular identity that did not segregate with the MSCs. 
The molecular signature that identified the fibroblasts comprised transcripts asso-
ciated with hyaluronic acid, aggrecan, collagen processing, collagen fibril anchorage 
points, the elastic networks, and some others [26]. Similarly, using next-generation 
RNA sequencing, Taşkiran and Karaosmanoğlu showed that human primary bone 
marrow MSCs and human primary dermal fibroblasts have different molecular 
signatures [27]. In particular, a large group of genes that have important roles in 
embryonic development were highly expressed in MSCs; e.g., the homeobox genes. 
Aristaless-like homeobox family member ALX1 and distal-less homeobox DXL1, 
5, and 6 are involved in craniofacial development, while short stature homeobox 
(SHOX) regulates expression of early osteogenic genes during cell differentiation. 
Taşkiran and Karaosmanoğlu suggested that MSCs are more appropriate for devel-
opmental and differentiation studies, compared to dermal fibroblasts [27].
Another feature that appears to be more attributed to MSCs is homing through 
migration. Intrinsic inflammatory characteristics have a pivotal role in stem-cell 
recruitment [28]. Bone marrow-derived MSCs have been demonstrated to migrate 
to the endometrium to contribute to the stem-cell reservoir and the regeneration of 
endometrial tissue [28]. Khatun et al. compared inflammation-driven migration of 
human bone-marrow-derived MSCs to MSCs and fibroblasts derived from the same 
niche (i.e., the endometrium). They showed that similar to bone-marrow-derived 
MSCs, endometrial MSCs showed high migration activity. However, the differentia-
tion process toward stromal fibroblasts resulted in minimal migration [28].
3. MSCs and fibroblasts: their roles in tissue injury
A schematic representation of the interactions between MSCs and fibro-
blasts is shown in Figure 3. Following tissue injury through bone fracture, joint 
trauma, muscle tears, and skin wounds, for example, a well-orchestrated series 
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of time-dependent and overlapping events takes place, including coagulation, 
inflammation, new tissue formation, and injury resolution. Each phase needs to be 
efficiently carried out to allow the further progression toward tissue regeneration.
MSCs can secrete a variety of cytokines and growth factors that have immuno-
suppressive and antifibrotic properties, which can have beneficial influences in the 
healing process [38]. The failure of tissue regeneration most commonly results in 
chronic inflammation and/or fibrosis, which leads to damage of the adjacent tissues 
and/or formation of inferior nonfunctional tissue. Some tissues have poor healing 
capacities if a wound extends beyond the epidermis, such as skin and cartilage, in 
particular. It is not entirely clear whether this is due to the absence or ‘exhaustion’ 
of the endogenous MSCs in these tissues, due to disease or age [39, 40]. Fibrosis, or 
scarring, is defined as accelerated accumulation of extracellular matrix factors, as 
predominantly collagen type I, which can prevent regeneration of tissue. This can 
occur in virtually any tissue as a result of trauma, inflammation, immunological 
rejection, chemical toxicity, or oxidative stress [38]. Following cartilage surface 
injury, the hyaline cartilage that is predominantly collagen type II is replaced by 
collagen type I, which lacks the functional properties of cartilage, such as shock 
absorption and reduction of friction in the joint.
The antifibrotic effects of MSCs are not entirely understood, and they are likely 
to overlap with the MSC anti-inflammatory and angiogenic properties [38, 41]. 
However, MSCs secrete several cytokines and growth factors that inhibit fibro-
blasts [42]. Hepatocyte growth factor released by MSCs has been shown to down-
regulate the expression of transforming growth factor-β1 (TGF-β1) and collagen 
type I and III by fibroblasts, and on the other hand, to up-regulate expression of 
matrix metalloproteinases 1, 3, and 13 in fibroblasts, thereby promoting turnover 
of the extracellular matrix [42]. In agreement with this, Yates et al. showed that 
Figure 3. 
Schematic representation of the interactions between MSCs and fibroblasts as observed in the in vitro studies. 
ECM, extracellular matrix.
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co-transplantation of MSCs and fibroblasts reduces scarring of wounds [43]. 
They transplanted xenogeneic MSCs and showed that these augmented fibroblast 
proliferation and migration, and the extracellular matrix deposition that is critical 
for wound closure; this co-transplantation also reduced inflammation following 
wounding, an effect that was greater than seen for MSCs or fibroblasts alone. These 
data suggested complementary roles of MSCs and fibroblasts to normalize matrix 
regeneration during healing, and they demonstrated that even transiently engrafted 
cells can have a long-term impact via matrix modulation and ‘education’ of other 
tissue cells [43].
Domaszewska-Szostek et al. recently reviewed the available data on the effi-
ciency of cell therapies for the treatment of chronic wounds, with these therapies 
including fibroblasts, keratinocytes, fibroblasts and keratinocytes together, 
bone-marrow-derived MSCs, and adipose tissue cells [44]. They showed that 
the majority of reports were on fibroblasts and keratinocytes, which included 
cell-based products that are already on the market. Based on the knowledge at the 
time, Domaszewska-Szostek et al. suggested that cell therapies in the treatment of 
chronic wounds showed immense potential. However, much is yet to be determined 
from both sides, in terms of both patients and cell therapies [44].
3.1 Skin injuries
While fibroblast-based substitutes have already been used in regenerative 
medicine, and in particular in regeneration of skin, a recent study by Paganelli 
et al. suggested that adipose-tissue-derived MSCs might represent a better 
alternative to fibroblasts in full-thickness skin injuries [29]. They showed that 
in-vitro adipose-tissue-derived MSCs produce a collagen- and fibronectin-con-
taining dermal matrix that is more abundant than for fibroblasts [29]. Moreover, 
adipose-tissue-derived MSCs also served as modulators in the regeneration 
of tissue that was inflamed or scarred secondary to injuries such as burns or 
trauma. Liu et al. investigated the effects of adipose-tissue-derived MSCs on 
keloidal disease, which is a particular type of scarring that is considered to arise 
from excessive proliferation of fibroblasts and extracellular matrix deposition 
[45]. They used a starvation-induced conditioned medium from adipose-tissue-
derived MSCs to treat human keloid-derived fibroblasts, and evaluated the 
fibroblast in-vitro proliferation, migration, and apoptosis. These human keloid-
derived fibroblasts showed inhibited proliferation and collagen synthesis. They 
also used a keloid xenograft implantation animal model to assess the paracrine 
effects of conditioned medium from adipose-tissue-derived MSCs in vivo. They 
noted reduced inflammation and fibrosis in an in-vivo keloid model, which was 
seen as keloid shrinkage and reduced inflammatory cell accumulation, blood 
vessel density, and collagen deposition [45].
Han et al. took things a step further, and included a photobiomodulation pre-
treatment of adipose-derived MSCs before collection of their conditioned medium. 
Photobiomodulation is a laser treatment that uses low power and energy, but has 
been shown to induce positive photobiological processes in cells, such as regulation 
of cell secretion, and promotion of cell proliferation, differentiation, and migra-
tion, with enhanced immunological functions, and therefore, accelerated tissue 
repair [46]. However, when they cultured hypertrophic scar and keloid fibroblasts 
in conditioned medium from adipose MSCs pretreated with photobiomodula-
tion therapy for 12, 24, and 48 h, there was inhibition of proliferation of these 
fibroblasts, and down-regulation of their profibrotic growth factors and collagen 
synthesis. They also suggested that the mechanism for this inhibition was related to 
down-regulation of TGF-β1 and Notch-1 expression [46].
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In addition to adipose-tissue-derived MSCs, bone-marrow-derived MSC 
have shown benefits for keloids and hypertrophic scars. Fang et al. showed that 
bone-marrow-derived MSCs use a paracrine signaling mechanism to attenuate 
the fibroblast proliferative and profibrotic phenotypes derived from hypertrophic 
scars and keloids, and to inhibit extracellular matrix synthesis [47]. Using condi-
tioned medium from bone-marrow MSCs, they showed significant inhibition of 
proliferation and migration of the fibroblasts from hypertrophic scars and keloids, 
in comparison with the use of conditioned medium from normal skin fibroblasts. 
Furthermore, they also reported that for conditioned medium from bone-marrow-
derived MSCs, for both of these types of fibroblasts, there was decreased expression 
of profibrotic genes, including those for connective tissue growth factor, plas-
minogen activator inhibitor-1, TGF-β1, and TGF-β2, and increased expression of 
antifibrotic genes, including those for TGF-β3 and decorin. Moreover, they reported 
decreased expression of collagen I and fibronectin and low levels of hydroxyproline 
in the cell culture supernatant, which suggested that the conditioned medium from 
bone MSCs suppressed the synthesis of extracellular matrix in these  
fibroblasts [47].
Similar data were reported by Sato et al. for amnion-derived MSCs. Following 
harvesting of keloid, mature and normal fibroblasts, and their stimulation with 
TGF-β, they showed that conditioned medium obtained from the amnion-derived 
MSCs prevented proliferation and activation of the keloid fibroblasts [48].
Tooi et al. used a similar study design; however, they used conditioned medium 
from human placenta-derived MSCs to harvest exosomes, and examined their 
effects on normal adult dermal fibroblasts in vitro [49]. Exosomes contain nucleic 
acids, proteins, and lipids, and function as an intercellular communication vehicle 
for mediation of the paracrine effects of MSCs [49]. They reported positive effects 
of this treatment, and in particular, significant up-regulation of stemness-related 
genes, such as octamer-binding transcription factor 4 (Oct4) and NANOG home-
box gene, and differentiation competence of fibroblasts to adipocytes and  
osteoblasts [49].
Hu et al. investigated the roles of exosomes derived from adipose MSCs in cuta-
neous wound healing [50]. In vitro, they showed that these exosomes can be taken 
up and internalized by fibroblasts, to stimulate cell migration and proliferation, and 
collagen synthesis, in a dose-dependent manner. In vivo, they demonstrated that 
these exosomes can be recruited to soft tissue wound areas in a mouse skin incision 
model, and that they significantly accelerated cutaneous wound healing. Following 
systemic administration of exosomes, they reported increased collagen I and III 
production in the early stage of wound healing, and inhibited collagen expression 
in the late stage, which might be favorable to reduce scar formation. Based on these 
results, they suggested that exomes can be used to facilitate cutaneous wound heal-
ing via optimizing the characteristics of fibroblasts [50].
Li et al. explored the paracrine effects of conditioned medium from umbilical-
cord-derived MSCs on dermal fibroblasts [51]. They showed that this treatment 
increased the proliferation and migration of fibroblasts. Moreover, they also 
reported on their transition into a phenotype with a low myofibroblast formation 
capacity, a decreased ratio of TGF-β1/3, and an increased ratio of matrix metal-
loproteinase/ tissue inhibitor of metalloproteinases. They also performed in-vivo 
wound healing assays. Full thickness skin excisional wounds treated with condi-
tioned medium from umbilical-cord-derived MSCs showed accelerated healing, 
with fewer scars seen.
Pan et al. investigated the effects of conditioned medium derived from human 
amniotic MSCs on hydrogen-peroxide-induced senescence of human dermal 
fibroblasts. They showed that the conditioned medium derived from these cells 
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significantly decreased senescence-associated β-galactosidase activity, and pro-
moted proliferation of senescent human dermal fibroblasts [52]. Interestingly, 
they also showed the same effect using conditioned medium from human amniotic 
epithelial cells. These cells were isolated from the same amniotic tissue, and char-
acterized by their similar immunophenotype to the MSCs, except for stage-specific 
embryonic antigen-4 as specific to MSCs, and their cobblestone-like morphology, in 
contrast to the MSC fibroblast morphology [52].
Gabrielyan et al. directly compared metabolically conditioned medium and 
hypoxia-conditioned medium derived from bone-marrow MSCs and skin fibro-
blasts, and evaluated their attraction of bone-marrow MSCs in two-dimensional 
migration assays [31]. They reported that the conditioned media from both types 
of cells had high concentrations of the angiogenic factors that are important for 
angiogenesis and cell migration. Having shown that both of the conditioned 
media produced by human skin fibroblasts attracted MSCs as efficiently as con-
ditioned medium produced by human bone-marrow MSCs, these authors favored 
fibroblasts-derived metabolic conditioning as providing easier, cheaper, and faster 
access to chemoattractive agents [31].
3.2 Diabetic wounds
There are also several studies that have suggested superior effects of MSCs 
compared to fibroblasts for the stimulation of diabetic wound healing [30, 53]. Jung 
et al. compared the treatment effects of human umbilical-cord-blood-derived MSCs 
with those of fibroblasts on diabetic wound healing in vitro [30]. Using co-culture 
of diabetic fibroblasts with either healthy fibroblasts or umbilical-cord-blood-
derived MSCs over 3 days, they measured cell proliferation and collagen synthesis 
and glycosaminoglycan levels, which are the major contributing factors to wound 
healing. The group treated with the umbilical-cord-blood-derived MSCs showed 
significantly greater collagen synthesis and glycosaminoglycan levels than the fibro-
blast-treated group [30]. Saheli et al. also focused on the interplay between MSCs 
and fibroblasts in diabetic wound healing, in both in-vivo and in-vitro diabetic 
models [53]. In vivo, in the group of diabetic wounds treated with MSC-derived 
conditioned medium, they demonstrated significantly greater wound closure, less 
pronounced inflammatory responses in the granulation tissue, better tissue remod-
eling, and more vascularization, compared with the nontreated diabetic wounds 
[53]. In vitro, they cultured human dermal fibroblasts in a high-glucose medium. 
When these fibroblasts were incubated in the presence of MSC-derived conditioned 
medium, they showed up-regulation of the genes encoding epidermal growth factor 
and basic fibroblast growth factor (bFGF), in addition to significantly greater cell 
viability/ proliferation, and migration. Based on these findings, they suggested 
that MSC-derived conditioned medium improves the activity of the fibroblasts in 
the diabetic microenvironment, and thus might promote wound repair and skin 
regeneration [53].
3.3 Ligament injuries
Similar to cartilage, ligaments have poor healing capacity due to hypocellularity 
and lack of cellular components for self-regeneration. Li et al. investigated differ-
entiation of human amnion-derived MSCs into human anterior cruciate ligament 
fibroblasts in vitro using a Transwell co-culture system and induction with bFGF 
and TGF-β1 [54]. Following an array of gene and protein expression for ligament-
specific molecules, they suggested Transwell co-cultures as an optimal system for 
differentiation of amnion-derived MSCs into ligament fibroblasts [54].
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3.4 Periodontal disease and jaw injuries
Osteoradionecrosis of the jaw is a severe chronic adverse effect of ionizing 
radiation therapy to the head and neck region. It is manifested as soft tissue fibrosis, 
chronic inflammation of the bone, and osteonecrosis of the maxillofacial region, 
with histopathological formation phases that are very similar to those of chronic 
wounds [55]. Zhuang and Zou reported inhibitory effects of irradiation-activated-
gingival fibroblasts on osteogenic differentiation of human bone-derived MSCs 
[56]. They showed that exosome-mediated delivery of miR-23a from irradiation-
activated fibroblasts inhibited osteogenesis of bone MSCs via directly targeting 
C-X-C motif chemokine ligand 12 (CXCL12) [56]. Under this pathological condi-
tion, rather than working hand in hand, fibroblasts and MSCs appeared to be on 
opposing sides of the tissue healing process.
A similar situation has been reported for periodontal diseases. These encompass 
a wide variety of chronic inflammatory conditions in the gingiva (i.e., soft tissue 
surrounding the teeth) and the periodontal connective tissues, such as the bone 
and ligaments [57]. Periodontal disease begins with gingivitis, as localized inflam-
mation of the gingiva that is initiated by bacteria in the dental plaque. If untreated, 
gingivitis can progress to loss of the gingiva, bone and ligaments, which creates 
the deep periodontal ‘pockets’ that are a hallmark of this disease, and which can 
eventually lead to tooth loss [57]. Periodontal ligaments have MSCs that can form 
fibroblasts, cementoblasts, and osteoblasts, and can thus be used for periodontal 
regenerative therapy. However, the fate of their differentiation is under the control 
of the periodontal cells, either via direct contact or via secretion of humoral factors. 
Kaneda-Ikeda et al. clarified the regulatory mechanism for MSC differentiation by 
humoral factors from gingival fibroblasts [58]. They indirectly co-cultured human 
ilium-derived MSCs with human gingival fibroblasts under osteogenic or growth 
conditions. Interestingly, they reported that humoral factors released by gingival 
fibroblasts suppressed osteogenesis of MSCs. This effect was regulated by miRNAs 
and undifferentiated MSC markers [58].
4. MSCs and fibroblasts: their roles in age-related tissue degeneration
With aging, and in particular with degenerative disorders of the musculoskeletal 
system such as osteoarthritis and osteoporosis, MSCs appear to be ‘exhausted’, 
with a lack of regenerative potential [33, 40, 59], or their regenerative potential is 
diverted from functional to production of nonfunctional cell types, such as adipo-
cytes and fibroblasts [60, 61]. Fibroblasts, on the other hand undergo hyperprolif-
eration resulting in age-related fibrosis of many tissues and organs, in particularly 
skin, lung, kidney, liver and heart [23].
4.1 Intravertebral disc degeneration
Degeneration of the intervertebral discs is strongly implicated as a cause of 
lower back pain, which has been shown to affect up to 85% of people at some point 
during their lives [62]. Although it is most commonly manifested in adulthood 
and its progression is closely linked to aging, changes in the cellular microenviron-
ment of the discs can begin as early as a few years after birth [62]. Inflammation 
has been correlated with degenerative disc disease, but its role in discogenic pain 
and hernia regression remains controversial. Inflammatory responses might be 
involved in the onset of the disease, although it is also crucial for maintenance of 
tissue homeostasis [63].
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Clinical studies that have used autologous or allogeneic MSCs to treat patients 
with back pain have reported some encouraging results [64]. There is also evidence 
that fibroblasts injected into the degenerated discs remain viable, and thus might 
represent an effective therapy for prevention or for delay of degenerative diseases of 
the discs. However these data were obtained in animal models only [65].
Shi et al. showed that transplantation of human dermal fibroblasts into degen-
erating intervertebral discs of rabbits can significantly increase the markers of disc 
regeneration (e.g., disc height, collagen type I and II gene expression, proteoglycan 
content). In comparison to transplantation of rabbit dermal fibroblasts, these 
results showed similar regenerative trends, but these trends did not reach signifi-
cant difference. This study also showed that the human cells transplanted into 
rabbit discs did not induce immune response in the rabbit cells [66].
4.2 Bone degeneration
In addition to disc degeneration, most elderly people develop bone loss with 
age [54]. The most common clinical manifestation of bone loss is osteoporosis 
associated with an increased risk of fractures, which can also lead to death. In 2017, 
new fragility fractures in the EU6 were estimated at 2.7 million, with an associated 
annual cost of €37.5 billion and a loss of 1.0 million quality-adjusted life years [67]. 
As osteoblasts have a central role in the process of bone formation, the direct repro-
gramming of fibroblasts into osteoblasts might be a new way to treat bone fractures 
in elderly individuals. Chang et al. recently reviewed a large body of literature and 
proposed several clinical applications of a direct conversion method for generating 
osteoblasts in patients [68]. Successful direct conversion of fibroblasts into osteo-
blasts was reported previously in 2015, using defined transcription factors, such 
as Osterix, runt-related transcription factor 2 (Runx2), Oct3/4, and L-myc [69]. 
Despite this, Chang et al. concluded that more work is needed to determine the best 
way to directly reprogram somatic cells into osteoblasts for optimal clinical use. 
They also suggested that in addition to successful fibroblast-to-osteoblast conver-
sion, future studies will need to consider the optimal cellular microenvironment to 
promote osteoblast survival and bone formation in patients [68]. The microenvi-
ronment is a common component and factor with immense importance for efficacy 
of cell therapies of any kind [70].
5. MSCs and fibroblasts: their roles in immunological disorders
5.1 Rheumatoid arthritis
Under normal conditions, the joint membrane, i.e. synovium represent the site 
of the two closely related cell types: i.e., fibroblast-like synoviocytes and synovial 
MSCs. These can work hand in hand as immunomodulatory cells to control the 
magnitude of immune responses. Rheumatoid arthritis is a chronic autoimmune 
disease that manifests as polyarthritis with joint destruction [71]. The main patho-
logical characteristic of this rheumatic disease is increased proliferation of fibro-
blasts and accumulation of inflammatory cells, which results in the formation of 
the ‘pannus’. Interestingly, based on the evidence from animal models, Matsuo et al. 
suggested that resident fibroblasts account for the pathology of rheumatoid arthri-
tis, and not bone-marrow-derived and circulating cells [71]. In addition, genetic 
lineage tracing studies have suggested that fibroblasts in rheumatoid arthritis 
originate from local proliferation of resident fibroblasts, differentiation of pericytes 
and MSCs, and transition of endothelial cells [71]. The main targets in this disease 
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are thus inflammatory cytokines and leukocytes. As MSCs are immunosuppressive, 
they have great potential in therapies for this inflammatory disease [72]. However, 
it appears that the swamping of the microenvironment in rheumatoid arthritis with 
inflammatory cells and cytokines causes loss of efficacy in the responses of the 
endogenous joint-resident MSCs to the exaggerated immune response. In addition, 
synovial fibroblasts are likely to derive from synovial-membrane-derived MSCs, 
which can also to give rise to fibroblast-like synoviocytes, as key players in perpetu-
ation of joint inflammation and destruction in rheumatoid arthritis [73].
5.2 Systemic sclerosis
Systemic sclerosis is a rare autoimmune rheumatic disease that is characterized 
by excessive production and accumulation of collagen in different tissues. The phys-
iopathology of systemic sclerosis has still not been completely elucidated, although 
roles for fibroblasts, endothelial cells, immune cells, and oxidative stress have been 
demonstrated [74]. Several studies have established the beneficial effects of admin-
istration of MSCs from various tissue sources in different preclinical models that 
are characterized by local or systemic fibrosis. Clinical studies are, however, still 
falling behind. On the other hand, MSCs from patients with systemic sclerosis have 
been shown to constitutively express factors that stimulate fibrotic and angiogenic 
processes. This might indicate that MSCs are altered by the environment secondary 
to the onset of the disease, or that they might participate in the physiopathology of 
the disease [75]. Hence, the rationale for using allogenic MSCs in systemic sclerosis 
(as well as in other autoimmune diseases) is based on the possibility that autologous 
MSCs will be altered in these diseases [74].
6.  MSCs and fibroblasts: how to boost their complementary tissue 
regeneration
6.1 In-vitro approaches
As MSCs represent rare cell populations in vivo, their in-vitro expansion is an 
often-unavoidable step in the preparation for these cell therapies. Currently, MSC 
expansion is most commonly achieved via cultivation on tissue culture plastics 
with the addition of 10% fetal bovine serum. Van et al. investigated the feasibility 
of human fibroblast-derived extracellular matrix as an alternative for in-vitro cell 
expansion [76]. Such fibroblast-derived extracellular matrix was obtained from 
decellularized extracellular matrix derived from in-vitro-cultured human lung 
fibroblasts. Using umbilical-cord-blood-derived MSCs, they directly compared 
cell cultivation on tissue culture plastics, fibronectin-coated tissue culture plastics, 
and human fibroblast-derived extracellular matrix. They showed that the last of 
these, the human fibroblast-derived extracellular matrix, improved cell prolif-
eration, migration, and osteogenesis, as well as the expression of stemness and 
engraftment-related markers of MSCs. Furthermore, they showed superior in-vivo 
effects of MSCs pre-conditioned on human fibroblast-derived matrix in an emphy-
sema animal model (i.e., a lung disease). Based on this, they suggested that human 
fibroblast-derived matrix represents a naturally derived biomimetic microenviron-
ment with potential for practical applications in regenerative medicine [76].
Adipose-derived MSCs represent the preferable autologous source of MSCs in 
regenerative medicine in general, due to their indispensability in adults. Sivan et al. 
standardized their in-vitro culture conditions for differentiation of adipose-derived 
MSCs into dermal-like fibroblasts, which can synthesize extracellular matrix 
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proteins [77]. Given that adipose-derived MSCs are multipotent in nature and 
might develop into undesirable tissues upon transplantation, the diverting of these 
MSCs to a more committed, fibroblast lineage appears like a better option in skin 
tissue engineering. To promote commitment of these MSCs into fibroblasts, they 
used a special biomimetic matrix composite that was pre-coated with fibrinogen, 
fibronectin, gelatin, hyaluronic acid, and human platelet growth factors. When 
MSCs were cultured on this composite with the presence of differentiation medium 
supplemented with fibroblast-conditioned medium and growth factors, they 
showed up-regulation of fibroblast-specific protein-1 and a panel of extracellular 
matrix molecules that were specific to the dermis, such as fibrillin-1, collagen I, 
collagen IV, and elastin. As fibroblasts derived from adipose MSCs can synthesize 
elastin, this is an added advantage for successful skin tissue engineering, compared 
to fibroblasts from skin biopsies [77].
To boost the combined tissue-healing effects of MSCs and fibroblasts, several 
tissue engineering approaches are being investigated. To enhance resistance to 
oxidative stress and the paracrine potential of MSCs, Costa et al. formulated 
MSC spheroids encapsulated in alginate microbeads [78]. This three-dimensional 
formulation showed increased angiogenic and chemotactic potential relative to 
encapsulated single cells. As the encapsulated MSCs promoted formation of tube-
like structures and migration of fibroblasts into the wounded area, these authors 
suggested that such a model setting can be used for wound repair and regeneration 
processes [78].
As oxygen represents an important factor in tissue healing, hyperbaric oxygen 
therapy is an effective adjunct treatment for ischemic disorders, such as chronic 
wounds. Engel et al. showed beneficial effects of hyperbaric oxygen therapy on 
mono-cultures and co-cultures of human adipose-derived MSCs and fibroblasts 
[79]. The results of this study suggested that hyperbaric oxygen therapy leads to 
immunomodulatory and proangiogenetic effects in a wound-like environment, 
where adipose-derived MSCs and fibroblasts collaborated toward efficient wound 
healing [79].
In addition to cell therapies where formulation for clinical use still represents 
immense challenges, great hope has also been put into the cell-free formulations 
for use in regenerative medicine. Several studies have explored the effects of 
conditioned media from various tissue-derived MSCs on fibroblasts (as described 
in 3.1). Conditioned medium is a cell-free formulation, and it basically defines the 
adult stem-cell secretome.The majority of studies that used conditioned medium 
to enhance fibroblast properties, harvested the medium from two-dimensional 
cultures of MSCs from various tissue sources. Using a polystyrene scaffold, Kim et 
al. created a three-dimensional culture of perivascular cells, which represented a 
more physiologically appropriate system to harvest conditioned medium [80]. They 
used this medium to investigate the effects on the migration and proliferation of 
human keratinocytes and fibroblasts. The migration of both of these types of cells, 
and also the proliferation of keratinocytes, were significantly greater with the con-
ditioned medium from this three-dimensional culture system. They also reported 
greater expression of type I collagen, specific expression of some other factors (e.g., 
thioredoxin), and more small particles such as CD63-positive extracellular vesicles, 
which were shown to stimulate keratinocyte migration. Based on these data, the 
three-dimensional cultures have the potential to be considered as future wound-
healing remedies.
An in-vivo alternative to conditioned medium produced by in-vitro cultured 
MSCs was tested by Cerny et al. [81]. They used wound fluid samples from 
fingertip injuries and split skin donor sites under occlusive dressings, to evaluate 
the effects of paracrine factors in the wound fluid (secretome) on migration and 
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proliferation of MSCs and fibroblasts. Under these conditions, MSCs showed sig-
nificant increases in both migration and proliferation, while fibroblasts showed a 
significant increase in migration only. Hence, the paracrine factors in the wound 
fluid can modulate the wound-healing process, and can reduce scar-tissue  
formation [81].
6.2 In-vivo approaches
When it comes to in-vivo approaches to stimulate endogenous MSCs and fibro-
blasts, platelet-rich plasma has been widely studied and is used in clinical practice. 
Platelet-rich plasma contains higher concentrations of platelets than whole blood, 
as typically three-fold to five-fold higher compared with normal plasma (normal: 
150,000 to 300,000 platelets per microliter) [82]. This platelet concentrate has 
been shown to have anti-inflammatory effects through growth factors, such as 
TGF-β and insulin-like growth factor 1, and also stimulatory effects on MSCs and 
fibroblasts [82].
Stessuk et al. evaluated the combined effects of platelet-rich plasma and con-
ditioned medium from adipose-derived MSCs on fibroblasts and keratinocytes 
in vitro. They showed significant proliferation of both cell types, and also signifi-
cant migration of fibroblasts treated with both components, which suggested the 
potential of this combination for healing and re-epithelialization of chronic wounds 
in vivo [83].
The major issue of unpredictable and difficult-to-replicate in-vivo effects of 
MSC therapies is most probably the microenvironment that these cell injections 
are delivered into. In healthy tissues, stem cells reside within a complex microen-
vironment that comprises cellular, structural, and signaling cues that collectively 
maintain stemness and modulate tissue homeostasis [70]. Following tissue injury, 
substantial changes are made to this unique cell environment, which will influence 
the regulation of stem-cell differentiation, trophic signaling, and tissue healing. 
Bogdanowicz and Lu reviewed recent studies on how microenvironmental cues 
modulate MSC responses following connective tissue injury, and how this micro-
environment can be programmed for stem-cell-guided tissue regeneration [70]. 
Based on their revised data, these authors suggested that the cell microenvironment 
should be conducive to stem-cell lineage commitment, biomimetic tissue regenera-
tion, and ultimately, restoration of physiological functions. In this light, specific 
attention should be directed to methods for standardization of experimental 
conditions both in vitro and in vivo, and in particular to optimization of cell seeding 
densities and cell sources [70].
To mimic the optimal microenvironment for MSCs, several novel technological 
approaches are being developed. Combining human fibroblast-derived matrix and 
the biocompatible polymer hydrogel (i.e., polyvinyl alcohol), Ha et al. demon-
strated cytocompatibility with human MSCs [84]. Moreover, this advanced wound 
healing therapy was shown to be efficient in full-thickness wound repair in a 
preclinical model [84].
6.3 Converting fibroblasts to MSCs
When it comes to vascular damage, vascular-wall-derived MSCs might be par-
ticularly well suited for resolution of such injuries. Recently, Steens et al. developed 
a method for direct conversion of human skin fibroblasts into vascular MSCs. They 
directed cell-fate conversion through induction of ectopic expression of the highly 
vascular MSC-specific HOX genes, including HOXB7, HOXC6, and HOXC8, while 
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bypassing pluripotency. The converted MSCs showed classical multipotent MSC 
characteristics in vitro (i.e., multipotency, clonogenicity), and were selectively asso-
ciated with vascular structures in vivo. With respect to their therapeutic potential, 
these cells suppressed lymphocyte proliferation in vitro, while in a mouse model of 
radiation-induced pneumopathy in vivo, they protected the mice against vascular 
damage, as also for ex-vivo cultured human lung tissue [85]. These data suggested 
an efficient strategy for treatment of vascular diseases, such as hypertension, 
ischemic diseases, vascular lesions, and others.
In addition to genetic manipulation to convert fibroblasts to MSCs, there is also 
a chemical method available to convert primary human dermal fibroblasts into 
multipotent, induced MSC-like cells. Using a defined cocktail of small molecules 
and growth factors, (six chemical inhibitors, plus TGF-β, bFGF, and leukemia 
inhibitory factor), Lai et al. converted human fibroblasts into inducible MSCs in 
a monolayer culture over 6 days, with 38% conversion rate [86]. The inducible 
MSCs behaved like primary bone-marrow-derived MSCs in terms of their multipo-
tency, clonogenicity, molecular signatures, and surface marker expression profile. 
Moreover, these MSCs were as effectively as bone-marrow-derived MSCs in their 
significant protection against fatality with endotoxin-induced acute lung injury in a 
mouse model. Based on these data, the authors suggested that this chemical conver-
sion of fibroblasts to MSCs is superior to the genetic approach, as this latter might 
have the risk of insertional mutagenesis [86].
7. Conclusions
The relative failure of decades-long endeavors to establish a clear definition 
for both MSCs and fibroblasts appears to be a result of the complementary and 
overlapping roles these cells have in cell homeostasis and tissue development and 
injury. Indeed, due to the similarities in their morphologies, immunophenotypes, 
and connective tissue stroma formation, MSCs and fibroblasts are indistinguishable 
in most in-vitro settings. However, in-vivo studies, and in particular recent studies 
using modern analytics such as next-generation sequencing, have indicated that a 
line can be drawn to distinguish between MSCs and fibroblasts. On the other hand, 
several studies have demonstrated that it is the cellular therapies that combine both 
of these cell types that represent the optimal approach for future development of 
tissue-regenerating strategies.
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